Anticancer agent 281 (TFA)

Anticancer agent 280 TFA (Compound 65) is an anti-cancer agent targeting triple-negative breast cancer (TNBC) . Anticancer agent 280 TFA exhibits IC50 values of Anticancer agent 280 TFA for MDA-MB-231, MDA-MB-231/LM2-4, Jurkat, and MCF-7 of 7.1, 11.65, 6.99, and 21.51 μM respectively. Anticancer agent 280 TFA can cause significant arrest of cells in the S phase and induce cell apoptosis. Anticancer agent 280 TFA can be used for the study of TNBC[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis

Related Pathways

Apoptosis

Field of Research

Cancer

Smiles

FC1=CC2=C(N(C3CC3)C=C(C(N[C@@H](CC(C)C)C(NC4=CC=C([N+]([O-])=O)C=C4Cl)=O)=O)C2=O)C=C1N5CC[NH2+]CC5.FC(F)(F)C([O-])=O

Molecular Formula

C31H33ClF4N6O7

Molecular Weight

713.08

References & Citations

[1]Azzman N, et al. Novel 4-quinolone derivative inflicted cytotoxicity via intrinsic apoptotic pathway activation on human metastatic triple-negative breast cancer cells. Bioorg Chem. 2025 Oct;165:109033.